Novo Nordisk A/S (NYSE:NVO) Shares Sold by First Horizon Advisors Inc.

First Horizon Advisors Inc. cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,664 shares of the company’s stock after selling 271 shares during the quarter. First Horizon Advisors Inc.’s holdings in Novo Nordisk A/S were worth $379,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Jennison Associates LLC grew its position in Novo Nordisk A/S by 100.3% in the third quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after acquiring an additional 11,727,507 shares during the period. FMR LLC increased its position in shares of Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after purchasing an additional 6,654,614 shares during the last quarter. Morgan Stanley raised its holdings in Novo Nordisk A/S by 96.5% in the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after buying an additional 4,526,199 shares during the period. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after buying an additional 4,350,862 shares during the last quarter. Finally, Polen Capital Management LLC purchased a new position in Novo Nordisk A/S during the third quarter worth about $718,995,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.8 %

NVO opened at $123.05 on Friday. The business has a fifty day moving average price of $127.20 and a 200 day moving average price of $112.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28. The stock has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 2.06 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. Sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on NVO shares. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. BMO Capital Markets started coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, UBS Group started coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.